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Abstract
Background: Orphan drugs are intended to treat, prevent or diagnose rare diseases. In recent years, China
healthcare policy makers and patients have become increasingly concerned about orphan drug issues. However,
very few studies have assessed the availability and affordability of orphan drugs for rare diseases in China. The aim
of this study was to provide an overview of the availability and affordability of orphan drugs in China and to make
suggestions to improve patient access to orphan drugs.
Methods: Two components of the availability of orphan drugs were examined. Market availability was assessed
by the extent to which orphan drugs were marketed in China with a comparison to orphan drugs in international
markets, such as the U.S., EU and Japan. We conducted surveys and collected data from 24 tertiary public hospitals
in China to measure hospital-level availability of orphan drugs. The affordability of orphan drugs was calculated
using hospital dispensary prices and was expressed as days of average daily income required for the cost of a
course of treatment. Affordability was also analyzed under the Chinese basic medical insurance system.
Results: Orphan drugs approved in the U.S., EU and Japan had 37.8 %, 24.6 % and 52.4 % market availability in China,
respectively. Median availability of 31 orphan drugs surveyed at the 24 tertiary public hospitals was 20.8 % (very low).
Within a periodic treatment course, the average treatment cost of 23 orphan drugs is approximately 4, 843. 5 USD, which
equates to 505.6 days of per capita net income for an urban resident with a middle income (187.4 days for a high-income
urban resident) or 1,582.8 days’s income for a rural resident with a middle income (657.2 days for a high-income rural
resident). Except for homoharringtonine, 22 orphan drugs for 14 rare diseases were unaffordable for the most of residents
in China. With 5 % out-of-pocket expenses, only three generics could be afforded by middle-income residents, whereas
seven drugs for high-income urban residents.
Conclusions: The Chinese government can take more responsibility for improving the availability and affordability of
orphan drugs through setting up incentive policies and public platforms for sharing of orphan drug information. Control
of the high price of orphan drugs, combined with a joint funding model from both government and private enterprise
can efficiently reduce the economic burden of affected patients in China.
Keywords: Rare disease, Orphan drug, Availability, Price, Affordability, China

Background
Rare diseases are diseases with low prevalence that affect a
very small proportion of the population [1]. These diseases
are often serious, chronically debilitating, life-threatening
or life-limiting [2] . Currently, there is no universally accepted definition of a rare disease. In the United States of
* Correspondence: shwgong@hust.edu.cn
1
Department of Pharmacy Business and Administration, School of Pharmacy,
Tongji Medical College of Huazhong University of Science and Technology,
Wuhan 430030, Hubei, China
Full list of author information is available at the end of the article

America (U.S.), rare diseases are defined as those diseases that affect less than 200,000 persons (prevalence
of < 0.64 ‰), whereas the definition shifts to an
affected population of less than 50,000 in Japan (prevalence of < 0.39 ‰) and less than 2,000 in Australia
(prevalence of < 0.1 ‰). In the European Union (EU),
rare diseases are defined as life-threatening or chronicdebilitating conditions that affect less than 5 in 10,000
persons. Generally, the prevalence rate of rare diseases
varies from about 1 to 6.4 in 10,000. Compared to the

© 2016 Gong et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Gong et al. Orphanet Journal of Rare Diseases (2016) 11:20

U.S., Japan, EU and Australia, the World Health
Organization (WHO) defines a rare disease based on a
higher prevalence: less than 6.5–10 in 10,000 [1].
Although any given rare disease affects a small percentage
of the population, cumulatively, these diseases have a large
impact as greater than 7, 000 different rare diseases have
been reported [2]. The total number of patients with rare
diseases is estimated to be approximately 30 million in
Europe and 25 million in North America [3]. According
to the definition of rare diseases recommended by WHO,
over 10 million patients have rare diseases in China,
estimated from a total population of at least 1.3 billion [4].
A drug that has been developed with the intent to diagnose, prevent or treat a rare disease may receive orphan
drug status in the U.S., Japan, EU and Australia [5]. It is
often very difficult for drug companies to quickly recover
the research and development costs of orphan drugs. In
1983, the first incentive legislation, Orphan Drug Act
(ODA) was passed in the U.S.. Currently, the ODA has
been created not only to offer hope for patients with rare
diseases, but also to foster a new mechanism of personalized drug and biotechnology development [6]. However,
orphan drugs are characterized by both low market share
and high price due to a low cost sharing population, which
usually leads to limited access to affected patients. For example, the U.S. pharmacy retail prices of Novoseven
(5 mg/1 kit), Gleevec (400 mg/30 tablets) were over
$9,200 and $7,000 in 2013, respectively [7]. Therefore, it is
very challenging to improve the affordability of these
drugs for patients. Due to the large number of rare
disease-affected patients in China, the shortage of orphan
drugs for these patients has become a major health
problem. Patients with rare diseases in China face a
double dilemma [8].
Availability and affordability are the two main criteria
to assess whether patients can receive timely, adequate
and efficient treatment. Some studies have examined the
availability and affordability of essential medicines for
common diseases using the standardized methodology
developed by the WHO and Health Action International
(HAI) in 2008 [9–12]. Compared to orphan drugs,
essential medicines are “those that satisfy the priority
health care needs of the population” [13]. In 1977, the first
“WHO Model List of Essential Medicine” identified 208
individual drugs which could provide safe, cost-effective,
affordable and time-efficient treatments for common
diseases. So far, the 19th WHO Model List released 409
essential drugs including innovative treatments for hepatitis C, breast cancer and leukemia, as well as multi-drug
resistant tuberculosis, etc. [14]. However, from the view of
disease prevalence, everyone has the potential to suffer
from a rare disease. Effective and safe orphan drugs are of
the utmost importance, and are indispensable for patients
with rare diseases. Most recent studies have focused on
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international comparisons of orphan drug policies and
regulations [15]. There has been a paucity of literature on
the availability and affordability of orphan drugs for rare
diseases in China. The objective of this study is to assess
the availability and affordability of orphan drugs in China.

Methods
Data sources

We conducted two types of data collection. Firstly, we
obtained three databases of orphan drug designations
and approvals from the U.S. Food and Drug Administration (FDA) [16], European Medicines Agency (EMA)
[17] and Japan Ministry of Health, Labour and Welfare
(MHLW) [18]. According to these lists of orphan drugs,
we confirmed their marketing authorization in China
based on the drug approval database from the China
Food and Drug Administration (CFDA) [19]. Using the
Anatomical Therapeutic Chemical (ATC) classification
system of the WHO to identify the ATC code for each
orphan drug [20], we confirmed the ATC codes and
calculated the category number of all orphan drugs
marketed in U.S., EU, Japan and China. If the WHO had
not defined the ATC code for an orphan drug, we
confirmed the ATC type based on the type of disease
treated by the orphan drug. We then compared the
status of orphan drugs for 14 rare diseases in the U.S.,
EU, Japan and China.
We also developed a survey questionnaire to collect
the price and availability information of each orphan
drug ( both “brand name” and generic drugs) in each
medical facility (such as tertiary public hospitals) based
on the methodology of the WHO/HAI manual (2008).
Data were collected by trained graduate students. These
students were supervised by survey managers and the
principal investigator. Responses on the survey forms
were recorded carefully on the day of data collection.
Selection of diseases and medications

Based on the rare diseases with the main orphan drug
approvals in U.S., Japan and EU countries, we selected 14
life-threatening and serious diseases that could be considered as rare diseases in China according to WHO definition [1, 5, 21]. According to the annual new drug review
reports of FDA, EMA, 14 rare diseases have orphan drugs
with substantial therapeutic value. Twenty-four orphan
drugs can be used to treat these 14 rare diseases, which
cover cancers, blood diseases, cardiovascular diseases,
metabolic diseases, endocrine diseases, neurologic diseases
and respiratory diseases. These orphan drugs are imiglucerase, sapropterin dihydrochloride, recombinant
coagulation factor VIII, coagulation factor VIIa, human
coagulation factor VIII, human prothrombin complex
concentrate, bosentan, Iloprost, ambrisentan, recombinant human growth hormone, busulfan, teniposide,
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mitoxantrone, imatinib, dasatinib, nilotinib, meisoindigo, arsenious acid, homoharringtonine, rituximab,
sorafenib, danazol, riluzole and poractant alfa. The 24
types of orphan drugs included 22 brand name drugs
and 9 generic drugs. (Additional file 1: Table S1 shows
the names of drugs surveyed and their indications.)
According to the definition of WHO/HAI (2008), a
brand name drug is a patented, pharmaceutical product
that has been authorized for marketing worldwide. A
generic drug is a pharmaceutical product that is “identical–or bioequivalent–to a brand name drug in dosage
form, safety, strength, route of administration, quality,
performance characteristics and intended use” [9, 22].
Survey and selection of medical facilities

We conducted a pre-survey of 14 public hospital pharmacies and 28 private pharmacies in Wuhan, Hubei Province
(per capita GDP in Wuhan is close to the median per
capita GDP in China). We surveyed both hospital dispensary prices and pharmacy retail prices in 14 public hospitals
and 28 private pharmacies in Wuhan. Our pre-survey results showed that most of the orphan drugs were only
available in tertiary public hospitals, and were rarely found
in secondary and primary hospitals. Only one orphan drug
(Busulfan) was found in 3 out of 28 private pharmacies.
Due to the unavailability of most orphan drugs, secondary
or primary hospitals and private pharmacies were excluded
from our final survey. Therefore, we would expect to find
orphan drugs at large and well-known hospitals, such as
public tertiary hospitals.
We surveyed the availability and prices of 24 orphan
drugs in 24 tertiary public hospitals in China. These orphan drugs covered 135 drug package sizes during our survey time period (March 2012 to August 2012) according to
the WHO/HAI methodology (2008). (Additional file 2:
Table S2 shows the questionnaire on the availability and
prices of orphan drugs for several serious rare diseases in
the surveyed hospitals). The 24 hospitals were selected
from 12 provinces and cities in the eastern, central and
western regions of China, including Qinghai, Xinjiang,
Sichuan, Yunnan (western region), Hubei, Anhui, Hunan
(central region), Fujian, Guangxi, Guangdong, Zhejiang,
and Beijing (eastern region). As public hospitals in China
have adopted a centralized pharmaceutical bidding and
distribution system through local governments to purchase
drugs, similar types of drugs were generally available at the
same level of hospital in each province. Hence, we believe
the 24 tertiary public hospitals are representative of all
tertiary public hospitals nationwide.
Ethics

The study was approved by the Ethics Committee of
Tongji Medical College, Huazhong University of Science
and Technology (No: IORG0003571). We informed all
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participants of the aims and plans of our study before
the survey. All participants provided their written
informed consent to participate in this study.
Measures and analysis
Availability

We measured orphan drug availability at both the national
and hospital level according to the WHO definition and
determinants of drug availability [23]. The market availability of an orphan drug at the national level was defined
as (i) numbers and types of approved orphan drugs in
China, the U.S., EU and Japan; and (ii) the marketing
situation of orphan drugs for 14 rare diseases to be authorized in China, the U.S., EU and Japan.
The hospital-level availability of orphan drugs was measured as the percentage of all surveyed public hospitals
that could supply a particular orphan drug on the day of
data collection, based on WHO/HAI methodology (2008).
According to the literature [11, 23], the following criteria
were used to describe the availability of orphan drugs:
 Absent, 0 % of facilities: these orphan drugs were

not found in any facilities surveyed;
 Very low, < 30 % of facilities: these orphan drugs

were very difficult to find;
 Low, 30–49 % of facilities: these orphan drugs were

somewhat difficult to find;
 Fairly high, 50–80 % of facilities: these orphan drugs

were available in many facilities;
 High, >80 % of facilities: these orphan drugs had

good availability.
High availability of orphan drugs at the hospital level
will help patients with rare diseases get timely and efficient treatment.
Affordability

According to WHO/HAI standard [9] , affordability can be
measured as the ability of residents to afford a treatment
course based on daily wages of the lowest-paid unskilled
government worker. Due to the lack of official data on
daily wages of the lowest-paid workers, we used disposable
income per capita of urban residents and net income per
capita of rural residents as proxy values [11]. Considering
the high price of some orphan drugs, we selected two
different income levels to reflect treatment affordability for
urban and rural residents. The two income levels represent
the average income of all residents and the average income
of the highest income residents, which represent the
middle-income and the high-income populations, respectively. In 2011, disposable daily income per capita of all
urban residents was 59.75 RMB (9.58 USD/day) versus
161.21 RMB (25.84 USD / day) for high income urban residents; daily net income per capita of all rural residents was
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19.12 RMB per day (3.06 USD / day) versus 45.98 RMB
per day (7.37 USD / day) for high income rural residents in
China [24]. If the cost of a course of treatment of an
orphan drug is one day’s income or less, it is considered
affordable and vice versa. Cost for a treatment course is
denoted in Eq. (1).
ð1Þ

The cost of an orphan drug treatment course

¼ Median price of unit dose of drug reported by facilities
 Drug daily dose  Days of a treatment course

The median price of unit dose is the median drug
dispensary price per unit dose. The median drug
dispensary price was not calculated until data had been
collected from at least three dispensaries among the 24
public tertiary hospitals surveyed (Additional file 3:
Table S3 shows the median price of each orphan drug
from the surveyed results of 24 public hospitals). We
used the clinical periodic treatment course of every orphan drug as the base-case analysis (Additional file 4:
Table S4 shows how the drug daily dose and treatment
course was calculated). We estimated the duration of a
periodic treatment course for each orphan drug based
on the package insert information, literature review and
expert medical opinions. We defined four weeks as a
course for chronic and rare conditions, such as PAH,
GHD, HAE, CML, ALL, AML, APL, NHL, RCC, ALS,
etc. The WHO defines the duration of a treatment
course as 7 days for an acute indication and 30 days for
a chronic indication. We used the WHO’s definition as
the sensitivity analysis. WHO also defines the Defined
Daily Dose (DDD) for some orphan drugs, which refers
to the average daily dose of a drug prescribed for its
major indication in adults. There are five orphan drugs
defined as DDD by WHO, including imiglucerase 300U,
bosentan 250 mg, iloprost 50 ug, danazol 600 mg,
riluzole 100 mg [20]. However, for most orphan drugs
surveyed, WHO does not provide information on the
DDD. We obtained the daily dose information from the
packet insert, medical literature and expert clinical opinions. DDD varies by the patients’ exact indication, body
weight and stage of disease. A maintenance dosage

regimen recommended in the manufacturer’s summary
of product characteristics (SPC) was used. If a disease
has different severity levels, we chose the dose for
moderate severity.

Results
Market availability of orphan drugs in China

Table 1 compares the number of orphan drug designations and approvals in U.S., EU, Japan and China. For
the 315 unique orphan drugs approved in the U.S. from
1983 to 2012, 119 received marketing approval in China.
The market availability rate in China was, therefore,
37.8 %. Among 65 unique orphan drugs that were approved for marketing in the EU between 2000 and 2012,
market availability in China was only 24.6 %. Among the
145 orphan drugs that were approved for marketing in
Japan from 1993 to 2012, market availability in China was
52.4 %. In total, of the 408 orphan drugs approved worldwide, 165 drugs were approved for marketing in China
(40.4 %). Of the 165 drugs approved in China, 114 (69.
1 %) were manufactured by the domestic pharmaceutical
producers in China. (Additional file 5: Table S5 lists the
situation of 165 unique orphan drugs marketed in China)
Table 2 compares the numbers of ATC therapeutic
categories of orphan drug approvals in U.S., EU, Japan and
China. As a result, the three most common types of orphan drugs marketed in four regions are antineoplastic
and immunomodulating agents, anti-infectives and drugs
acting on the digestive and metabolic systems. Rare cancer
was the most common therapeutic area and 80 orphan
drugs were used to treat rare cancers. Among the antineoplastic drugs, 56.3 % are used to treat hematopoietic cancers, and 51.1 % of antineoplastic drugs for hematopoietic
cancers have been marketed in China. The top three
groups of drugs with the highest market availability rate in
China are drugs acting on the genito-urinary system and
sex hormones, anti-infectives for systemic use and the
musculoskeletal system. However, there was a high CV
percent (>25 %) among the different types of orphan drugs
marketed in China.
To determine the availability of orphan drugs in China,
we further compared the year of launch of each drug with

Table 1 The number of orphan drug designations and approvals in U.S., EU, Japan and China
Regions (Time range)

Number of orphan
drug designations

Number of orphan
drug approvals
for marketing

Number of unique
orphan drugs approved
for marketinga (A)

Number of unique
orphan drugs marketed
in Chinaa (B)

U.S. (1983–2012.12.31)

2741

425b

315

119

37.8

EU (2000–2012.12.31)

1098

65

65

16

24.6
52.4

c

Japan (1993–2012.12.31)

300

185

145

76

Total

4132

675

525

211

a

408
a

165

Market availability
rate in China
[(B)/(A) × 100 %]

40.2
a

40.4

:A unique drug may have multiple approvals for different rare indications. bNot excluding withdrawals of designations and approvals of four orphan drugs.
c
Excluding revoked products
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Table 2 ATC Categories of orphan drugs marketed in the U.S., EU, Japan and China
ATC Category

A-Alimentary tract and metabolism

Orphan drugs
of China/U.S.

Orphan drugs
of China/EU

Orphan drugs
of China/Japan

Orphan drugs of
China/U.S. + EU + Japanb

N

%

N

%

N

%

N

%

6/42

14.3

1/12

8.3

6/19

31.6

10/43

23.3

B-Blood and blood forming organs

7/40

17.5

1/3

33.3

4/11

36.4

9/31

29.0

C-Cardiovascular system

6/9

66.7

1/5

20.0

4/7

57.1

6/13

46.2

D-Dermatologicals

1/4

25.0

0/0

-

0/0

-

1/4

25

G-Genito-urinary system and sex hormones

8/10

80.0

0/1

0

1/2

50

7/10

70

H- Systemic hormonal preparations, excluding sex
hormones and insulins

15/36

41.6

1/3

33.3

3/7

42.9

9/19

47.3

J- Anti-infectives for systemic use

12/32

37.5

0/2

0

28/43

65.1

32/58

55.2

La- Antineoplastic and immunomodulating agents

53/136

39.0

10/28

35.7

40/66

60.6

55/124

44.4

L1 for blood cancers

20/45

44.4

6/13

46.2

12/18

66.7

23/45

51.1

L2 for other cancers

23/43

53.5

4/9

44.4

6/12

50.0

16/35

45.7

M- Musculoskeletal system

5/12

41.7

0/0

-

2/7

28.6

6/12

50.0

N- Nervous system

9/31

29.0

1/6

16.7

3/11

27.3

10/33

30.3

P- Antiparasitic products, insecticides and repellents

4/17

23.5

0/0

-

2/3

66.7

5/12

41.7

R- Respiratory system

2/10

20

0/2

0

1/3

33.3

2/9

22.2

S- Sensory organs

2/8

25

0/0

-

1/4

25

5/12

41.7

V- Various

9/34

26.5

1/3

66.7

1/2

50

8/28

28.6

c

TOTAL

139/421

33.0

16/65

24.6

96/185

52.4

165/408

40.4

Coefficient of Variation(C.V.)

-

53.7

-

84.5

-

33.8

-

35.1

N: Number. La: includes L1 and L2 drugs. b: Number of unique orphan drugs approved for marketing in the U.S., EU and Japan. c: Excluding withdrawals of
designations and approvals of four orphan drugs

other countries. Among 165 orphan drugs approved in
China, 142 drugs (86.1 %) were approved from 1986 to
2008 in the U.S., EU or Japan. The number of targeted
orphan drugs for 14 rare diseases surveyed in the U.S., EU
and Japan were 64, 17 and 29 respectively. In total, there
were 71 orphan drugs which can be used to treat these 14
rare diseases. Out of 71 orphan drugs for 14 rare diseases,
35(49. 3 %) were not available in China at the time of the
survey, for example, miglustat, icatibant, ecallantide.
(Additional file 6: Table S6 shows the 35 unauthorized
orphan drugs for 14 rare diseases in the China.)
As shown in Table 3, 36 out of 71 orphan drugs were
available in China (marketing availability rate 50.7 %).
However, 31 out of 36 orphan drugs (86.1 %) had a
delayed market launch in China. The average time of delay
to market authorization was 7.7 years. The shortest delay
to market authorization was 1 year (Poractant alfa) and the
longest delay was 19 years (Pegaspargase). Two orphan
drugs were released in the same year in China, which is
also the first country they were launched.
Futhermore, eight drugs for six rare diseases were marketed only in China. Four out of eight drugs were firstly
approved in China, including arsenious acid, homoharringtonine, meisoindigo, calf-pulmonary surfactant for
injection. Table 3 also shows that 19 ophan drugs which

were approved as a new molecular entity (NME) or new
biological entity (NBE) by the FDA receieved marketing
approval in China.
The availability of orphan drugs at a hospital level

In China, drug procurement in tertiary public hospitals
depends on the centralized pharmaceutical bidding system
of provincial governments. In 2011, 120 out of 165 orphan
drugs were covered by at least one government’s centralized bidding system (Additional file 5: Table S5 shows the
number of procurement provinces for 120 orphan drugs).
To further investigate the actual availability of orphan
drugs in 2012, we surveyed and summarized data from 24
public tertiary hospitals that are representative of the
national situation and presented the results in Table 4.
Overall, the median availability rate of all orphan
drugs surveyed was 20.8 %, with 18.9 % for brand
name drugs and 45.8 % for generics. Four approved
drugs including ambrisentan, somatropin, dasatinib
and meisoindigo were not available in the hospitals
surveyed. Nineteen orphan drugs (15 brand names, 5
generics) were found to be available in less than 50 %
of all hospitals surveyed. Seven orphan drugs (3 brand
names, 4 generics) were available in > 50 % of the
surveyed hospitals.
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Table 3 Market availability status of orphan drugs for 14 rare diseases in the U.S., EU, Japan and China
ATC
Code

Generic name (Brand name)

Indication

Year marketing
authorization received
China

A16AB02

b

Imiglucerase (Cerezyme) P

GD

2008

Delay of release in China
(in years) Compared to the
earliest time

U.S.a

EUa

Japana

1994

d

1998

14

A16AX07

Sapropterin Dihydrochloride (Kuvan) P

PKU

2010

2007

2008

–

3

B02BD02

Human coagulation factor VIIIe

HEM

2002

–D

–

–

–

B02BD02

Recombinant coagulation factor VIII (Kogenate FS)

2010

–D

–D

–

–

–

Human prothrombin complex concentrate (e, Kcentra)

2002

2013

–

–

−11

B02BD04

Coagulation factor IX ( Benefix)c

2012

1997

D,

d

2009

15

B02BD05

Coagulation factor VIIa ( Novoseven)

2010

1999

D,

d

2000

11

b

e

2001

1994

–

–

7

2011

2001

2002

2005

10

H01BA02

Desmopressin acetate spray ( , Stimste)

C02KX01

Bosentan (Tracleer)b

B01AC19

Beraprost sodium (Dorner)

2008

–D

–D

1999

9

B01AC11

Iloprost inhalational solution (Ventavis)b

2007

2004

2003

–

5

C02KX02

Ambrisentan (Volibris/Letairis)b

2010

2007

2008

2010

3

B01AC21

Treprostinil (Remodulin)b P

2014

2002

–

–

12

G04BE08

Tadalafil (Cialis® / Adcirca®)

2009

2009

d

–

0

HAE

2002

–

–

–

–

GHD

1999

2000

–

1997

2

PAH

e

G03XA01

Danazol

H01AC01

RDNA origin somatropin
(e,Norditropin SimpleXx/Norditropin)

H01AC01

Somatropin (Saizen)

2000

1996

–

–

4

H01AC01

Somatropin (Genotropin)

2000

1997

–

1997

3

H01AC01

Somatropin (Humatrope) P

2002

1987

–

–

15

–

Recombinant human growth hormonee

2006

–

d

–

–

L01AB01

Busulfan (Busulfex/Busilvex ) P

L01XE01

Imatinib (e, Glivec/Gleevec)b P

L01XE06

Dasatinib (e, Sprycel)b P

2011

2006

2006

2009

5

L01XE08

Nilotinib (Tasigna)b

2009

2007

2007

2009

2

2010

–

–

–

–

2002

2014

2012

–

- 10

CML

2002

1999

2003

2006

3

2010

2001

d

2001

9

–

Meisoindigo

L01BB02

Mercaptopurine (e, Xaluprine)

L01AA01

Cyclophosphamide (e, Endoxan)

2001

–D

–

2003

-2

L01CB02

Teniposide (e, Vumon)b P

1999

1992

–

–

7

L01XX24

Pegaspargase (e, Oncaspar)c

2013

1994

–

–

19

L01XE01

Imatinib (e, Gleevec / Glivec)

2010

2006

d

2001

9

2011

2006

2006

2009

5

2001

1987

–

–

14

ALL

e

L01XE06

Dasatinib ( , Sprycel)

L01DB07

Mitoxantrone HCl (e, Novantrone)b

AML

L01DB06

Idarubicin HCl ( , Zavedos/Idamycin) P

2002

1990

–

–

12

L01BC01

Cytarabine (e, Cylocide N)

2000

–

–

2000

0

–

Homoharringtonine

2002

–D

–D

–

–

–

Arsenious Acid (Yitaida)

2010

–

–

–

–

–

8

1995

7

e

b

e

APL
b

L01XX27

Arsenic Trioxide ( ,Trisenox) P

2008

2000

d

L01XX14

Tretinoin (e,Vesanoid) P

2002

1995

–

–

Homoharringtonine

2002

–D

–D

–

–

L01XC02

Rituximab (MabThera/Rituxan)c

2000

1997

d

2001

3

NHL
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Table 3 Market availability status of orphan drugs for 14 rare diseases in the U.S., EU, Japan and China (Continued)
L01XE05

Sorafenib (Nexavar)b P

L01XC07

Bevacizumab (Avastin)

N07XX02

Riluzole (e, Rilutek)b P

RCC

ALS
b

R07AA

Poractant alfa (Curosurf)

–

Calf pulmonary surfactant (Kelisu)

a

2005

2006

–

6

2012

2009

d

–

3

2010

1995

d

1998

15

2000

1999

–

–

1

2010

–

–

–

–

2011

PIRDS
b

c

:Drugs were approved as an orphan drug; :NME, new molecular entity as defined by the FDA; :NBE, new biologic entity as defined by the FDA; D: Orphan drug
designation authorized; P: The drug received FDA priority drug review. d:The drug was intended for rare diseases in Europe with European market authorization
without priority designation of orphan drug in Europe; e:The drug had a generic equivalent in China

Of the 31 orphan drugs surveyed, 23 had pricing information and were available in at least three hospitals. The
unit prices of branded and generic orphan drugs surveyed can be found in Additional file 2: Table S2.
The affordability of orphan drugs

In 2011, the average unit procurement price of the 120
orphan drugs was between $0.00003 and $881.3, compared to $0.002 and $881.3 for the orphan drugs surveyed
(Additional file 5: Table S5 shows the procurement price
of the 120 orphan drugs). The average unit procurement
price of 21 orphan drugs was lower than $0.002. Table 5
presents the hospital dispensary prices, cost of treatment
and affordability of orphan drugs surveyed in 2012.
Among the 23 orphan drugs with pricing information
from at least three hospitals we analyzed, homoharringtonine is the only drug that would be affordable to an urban
resident, with the treatment cost being less than one day’s
income. The other 22 orphan drugs were unaffordable
to either urban or rural resident with a middle income
in China. Among those drugs that are unaffordable,
NovoSeven is the most unaffordable, followed by
Rituximab, Sorafenib tosylate, Imatinib and Bosentan.
Within a periodic course of treatment, the average treatment expenditure for the 23 orphan drugs was 4,843.5
USD, which is the equivalent of 505.6 days of per capita
net income for an urban resident with a middle income

(187.4 days for a high-income urban resident) and
1,582.8 days’s income for a rural resident with a middle
income (657.2 days for a high-income rural resident). We
also tested the change in affordability by using the WHO’s
definition of a drug treatment course - either 7-days or
30-days. The results are quite unaffordable when the cost
for a 7-day or 30-day course was analyzed. All 23 orphan
drugs had higher cost and were unaffordable to either
urban or rural resident with a middle income.
We further analyzed the data by accounting for the
healthcare insurance system in China. Taking the Urban
Employees’ Basic Medical Insurance Scheme (UEBMIS)
as an example, the coverage range and reimbursement
rate of UEBMIS is higher than the other two Chinese
medical insurance schemes, namely the Urban Residents’
Basic Medical Insurance Scheme (URBMIS), and the
New Rural Cooperative Medical Insurance Scheme
(NRCMIS). UEBMIS covers the Part A and Part B drugs
listed by the National Basic Medical Insurance [25].
For example, human coagulation factor VIII and homoharringtonine are covered in the Part A list, which are free
for beneficiaries covered by UEBMIS. There are 9 orphan
drugs covered in the Part B list. Generally, the beneficiaries
of UEBMIS need to pay for Part B drugs at a certain outof-pocket rate, which often ranges from 5 to 20 % in different provinces depending on local regulations. For essential
drugs, they are covered by the three insurance schemes

Table 4 Availability of brand name and generic orphan drugs surveyed in 24 public tertiary hospitals in China
Availability

Range

Originator Brands (Brand Name)

Generics

Absent

0

Ambrisentan (Volibris), Somatropin (Genotropin),
Dasatinib (Sprycel), Meisoindigo

None

Very low

<30 %

Imiglucerase (Cerezyme), Sapropterin dihydrochloride
(Kuvan), Coagulation factor VIIa (Novoseven), Bosentan
(Tracleer), Iloprost (Ventavis), Somatropin (Saizen),
Somatropin (Humatrope), Busulfan(Busulfex), Imatinib
Mesylate Cap (Glivec), Nilotinib (Tasigna), Riluzole ( Rilutek)

Teniposide, Riluzole taba, Riluzole capa

Low

30–49 %

Recombinant coagulation factor VIII (Kogenate FS),
Imatinib mesylate Tab (Glivec), Arsenious acid(Yitaida),
Sorafenib (Nexavar)

Human coagulation factor VIII, Danazol

Fairly high

50–80 %

Teniposide (Vumon), Rituximab (MabThera), Poractant
alfa (Curosurf)

Human prothrombin complex concentrate, Recombinant human
growth hormone, Mitoxantrone, Homoharringtonine

High

80 %

None

None

a

:Tab: Tablets, Cap: Capsules

Generic name (Brand name)

Median Unit Daily
PriceA (USD) Dose

Duration of Treatment Total Course Days of per capita net income
Course (days)
Cost (USD)
Urban Resident Affordability Rural Resident
Ave3

High4

Y/N

Recombinant human coagulation factor 0.85/IU
VII (Kogenate FS)

1750 IU 2

2961.5

309.1

114.6 N

Recombinant human coagulation factor 869.02/mg
VIIa (NovoSeven)B

50.4 mg 1

43798.7

4571.9

1695.0 N

Ave

High

967.8

Affordability

Coverage of Affordability
NBMI (Y/N) (if 5 % OOP)
Ave Urban High
(Y/N) (Y/N)

Y/N

401.8 N

14313.3 5942.8 N

Y, Part B

N

N

N

N

N

Bosentan (Tracleer)

0.75/mg

250 mg 28

5272.4

550.4

204.0 N

1723.0

715.4 N

N

N

N

Iloprost (Ventavis)

4.38/ug

50ug

28

6129.5

639.8

237.2 N

2003.1

831.7 N

N

N

N

28

Somatropin (Saizen)

10.89/IU

7 IU

2134.3

222.8

82.6 N

697.5

289.6 N

N

N

N

Busulfan (Busulfex)

4.66/mg

224 mg 4

4178.5

436.2

161.7 N

1365.5

567.0 N

Y, Part B

N

N

Imatinib (Glivec)

0.32/mg

600 mg 28

5384.6

562.1

208.4 N

1759.7

730.6 N

N

N

N

Imatinib (Glivec)

0.32/mg

600 mg 28

5438.5

567.7

210.5 N

1777.3

737.9 N

N

N

N

Nilotinib (Tasigna)

0.26/mg

800 mg 28

5779.5

603.3

223.7 N

1888.7

784.2 N

N

N

N

Teniposide (Vumon)

0.56/mg

102 mg 5

286.1

29.9

11.1 N

93.5

38.8 N

N

N

Y

Arsenious acid (Yitaida)

2.32/mg

10 mg

28

650.6

67.9

25.2 N

Rituximab (MabThera)

6.1/mg

91.1 mg 28

15558.2

1624.0

602.1 N

5084.4 2111.0 N

212.6

88.3 N

2451.8 1018.0 N

#

Y, Part B

N

N

N

N

N

Sorafenib tosylate (Nexavar)

0.33/mg

800 mg 28

7502.6

783.2

290.3 N

N

N

N

Poractant alfa (Curosurf)C

4.8/mg

525 mg 1

2456.7

256.4

95.1 N

802.8

333.3 N

Y, Part B

N

N

Human coagulation factor VII

0.3/IU

1750 IU 2

1065.7

111.2

41.2 N

348.3

144.6 N

Y, Part A

N

N

Human prothrombin complex
concentrate

0.15 IU

3150 IU 2

969.2

101.2

37.5 N

316.7

131.5 N

Y, Part B#

N

N

Danazol

0.004/mg

600 mg 28

61.9

6.5

2.4 N

20.2

8.4 N

Y, Part B

Y

Y

725.6

75.7

28.1 N

237.1

98.5 N

Y, Part B

N

N

223.1

23.3

8.6 N

72.9

30.3 N

Y, Part B

N

Y

Y, Part B

Y

Y

N

N

Y

Recombinant human growth hormone

3.7/IU

7 IU

Teniposide

0.44/ mg

102 mg 5

28

Mitoxantrone

1.24/mg

10.2 mg 4

50.6

5.3

2.0 N

16.5

6.9 N

Riluzole

0.16/mg

100 mg 28

453.2

47.3

17.5 N

148.1

61.5 N

309.6

32.3

12.0 N

101.1

42.0 N

0.4 Y

3.1

1.3 N

187.4 –

1582.8

657.2 –

Riluzole

0.11/mg

100 mg 28

Homoharringtonine

0.75/mg

2.5 mg

5

Average

–

–

17.2

9.4
4843.5

0.98
505.6

N

N

Y

Y, Part A#

Y

Y

–

–

–
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1.C/T: capsules/tablets, Inj: injection, Inh: inhalants. 2. In the calculations, we used the following average values: adult weight at 70 kg, children 15 kg, baby 1.5 kg; the body surface area at 1.7 m2. A: Use the minimum
specifications as the standards about the investigated drugs. Translated the price and took the median values as analysis objects; B: Recommended dose is 90ug/kg, 8times a day. C: Birth weight used was 1.5 kg. The
first dose is 150 mg/kg; repeat dose is 100 mg/kg, only one day usage. 3. “Ave”: a resident with per capita net income of average income households. 4. “High”: a resident with per capita net income of highest income
households. Y=Yes N=No. “NBMI”: National Basic Medical Insurance. “Part A” or “Part B” means a drug is covered by the Part A or Part B drug list of National Basic Medical Insurance. “OOP”: out-of-pocket expenses.
“#”: a drug is a national essential medicine of China
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Table 5 Affordability of orphan drugs in China
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with the lower out-of-pocket rate. Of 165 orphan drugs, 22
were national essential drugs of China. There were three
essential drugs among 31 orphan drugs surveyed. However,
at a 5 % out-of-pocket rate of drug cost, only three generic
drugs are affordable to residents with middle incomes,
whereas seven orphan drugs for high-income urban
residents.

Discussion
In the present study, we have performed an international
comparative analysis of orphan drug availability in the
U.S., EU, Japanese and Chinese markets. Using the
WHO/HAI methodology, we determined the availability,
price and affordability of orphan drugs from surveyed
information in 24 tertiary public hospitals in China.
There are four main findings from our research.
Firstly, the market availability of orphan drugs was relatively low in China when compared to other countries.
Among the 408 unique orphan drugs approved in the
world, only 40.4 % of these are available in China. The
majority of the orphan drugs marketed in China are
used to treat cancers. The drug with the highest market
availability rate in China acts on the genito-urinary system. The availability of orphan drugs marketed in China
differs greatly depending on the disease being treated.
Secondly, most orphan drugs authorized in other countries within the past 5 years have not been launched in
China yet. Compared to the earliest launch time across
the world, the average delay in market authorization of
31 orphan drugs for 14 rare diseases in China was
7.7 years. Thirdly, the median availability rate of 24
orphan drugs surveyed for 14 rare diseases in 24 top
hospitals in China was low (20.8 %). The hospital availability rates of generics were higher than for branded
orphan drugs. Finally, it can clearly be seen that there is
a substantial economic burden for patients with rare
diseases in China. The average treatment expenditure
for the 23 orphan drugs equates to 187.4 days of per
capita net income($ 25.84/day) for a high-income urban
resident. Compared to essential drugs, Jiang’s study
found the average treatment cost of 13 original brands
and 16 lowest-priced generics for 11 common diseases
equated to 3.27 days’ wages and 1 day’s wages ($ 4.70) in
the public hospitals in Shaanxi Province in 2012 [12].
Both urban and rural residents with middle incomes
could not afford the cost of most orphan drugs surveyed,
let alone those with lower incomes. With 5 % out-ofpocket expenses, only seven drugs could be afforded by
high-income urban residents.
Therefore, the reasons for low market availability, low
public hospital availability and low affordability of orphan drugs in China deserve further discussion. Lack of
R&D and supply incentive policies for orphan drugs are
possible reasons that lead to low market availability.
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Under a market-oriented economy, due to a small market
share of orphan drugs, most pharmaceutical manufacturers are not willing to invest in R&D and the production
of orphan drugs without an incentive policy. In addition,
since most rare diseases are caused by DNA mutations or
are recessive genetic diseases [26], their diagnosis, treatment and drug R&D often depend on more funding and
more advanced scientific instrumentation, which means a
greater risk of investment and manufacturing. Currently,
there is no incentive policy for R&D, production or the
importation of orphan drugs in China. Our findings reveal
a positive association between the number of marketed
orphan drugs and the number of incentive policies in the
U.S., EU and Japan.
There are further obstacles that contribute to the low
availability rate of orphan drugs at the hospital level in
China. Firstly, there is a lack of knowledge on rare diseases and training for medical doctors, e.g. diagnostic
methods and clinical guidelines. Rare diseases are often
under-diagnosed or misdiagnosed, especially in Chinese
rural areas with less well-qualified medical professionals
[27]. Under the current three-tier structure system of
hospitals, primary care hospitals are still not performing
optimal gatekeeping and referral roles [28]. Patients with
rare diseases are more likely to miss out on effective and
timely treatment with orphan drugs in the higher-level
hospitals. Secondly, there are no public national or provincial networks for rare diseases or orphan drugs for the
sharing of useful information in regards to these diseases,
e.g. treatment information or supply information. Thirdly,
in China, there are no specific procurement policies available for orphan drugs, no specifications for orphan drug
use and no fixed suppliers of orphan drugs, e.g. wholesalers
and manufacturers, as well as no uniform price control
mechanisms. Fourthly, in hospital pharmacies, specific
management organization and measures for orphan drugs
are not currently established. Lastly, due to the special
market attributes of orphan drugs, e.g. low market volume,
low profit, low turnover rate, high price and high transaction cost (high search cost), hospitals tend to have limited
interest in purchasing orphan drugs [29].
The low affordability of orphan drugs may be closely associated with many factors, e.g., high drug price, tendency
to use brand name drugs at hospitals, lack of insurance
coverage, low reimbursement rates, and low income level
for Chinese residents. These specific reasons could also be
used to explain the different distributions of rare diseases
and the availability of orphan drugs in different regional
hospitals.
Our research emphasizes the need for future policy
efforts to improve orphan drug availability, insurance
coverage and to decrease drug prices in China. Further
research is needed to clearly define rare diseases and orphan drugs using genetic testing and essential diagnostics
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to achieve accurate diagnosis of rare diseases [14, 30], to
formulate a list of available orphan drugs and to develop
incentive policies for orphan drugs. Future studies may
focus on the feasibility and applicability of incentive policies for orphan drugs in China, based on the experience
obtained in the regulation of orphan drugs in the US, EU,
Australia, Japan and Singapore. Incentive policies should
be directed towards those orphan drugs with low market
or hospital availability, try to improve the efficiency of
production and supply of orphan drugs and disseminate
more information about orphan drugs and rare diseases to
patients and doctors. More specific incentive systems are
also needed to establish targeted subsidies for the production and supply of orphan drugs, which may include filing
and reporting systems for orphan drug companies. Furthermore, import tariff exemption systems for orphan
drugs and free public platforms for sharing orphan drug
information from R&D to drug use for all the stakeholders
also require development.
Given the low affordability of orphan drugs in China,
more research is required to formulate policies to control
the price of orphan drugs, to increase insurance coverage
for rare diseases and to increase social relief funding. Previous studies have suggested several ways to lower orphan
drug prices and costs. Barak et al. suggested lower market
costs and enhancement of the close relationship among
patients, medical personnel, key opinion leaders and advocacy groups may improve market access for orphan drugs
[31]. Michel et al. found a greater number of available alternatives and increased competition from manufacturers
may also decrease the prices of orphan drugs [32].
European countries have developed methods to control
the prices of orphan drugs. Based on the results of an
availability survey for orphan drugs in the EU and recommendations on the EU Pharmaceutical Forum of 2008,
Eurordis suggested that an expert working group should
be established to assess the relative effectiveness of each
orphan drug, according to the added therapeutic value
and negotiate an EU ex-factory reference price with manufacturers [33, 34]. The French Economic Committee
signed an agreement with the pharmaceutical industry to
restrict the annual cost of orphan drugs to €50,000 per
patient. In Spain, a maximum price at which hospitals can
buy orphan drugs is maintained at the national level [32].
As for the evaluation of pricing and reimbursement
for new orphan drugs, Hughes-Wilson et al. proposed a
new assessment system based on several criteria that can
be used to evaluate newly developed orphan drugs at the
time of pricing or reimbursement. These criteria include
disease rarity, severity, the availability of other alternatives, the effectiveness of the new treatment, the cost of
research undertaken by the developer, as well as other
factors, such as manufacturing complexity and follow-up
measures required [35].
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Orphan drugs are often cost-ineffective at the priced
levels compared to common drugs [36]. Some studies
have suggested that cost-effectiveness analyses used to
assess the reimbursement of orphan drugs also need to
take into account health equity, societal values, therapeutic necessity, and the use of hierarchical methods in
allocation of health resources [31, 37].
Several cost risk-sharing programs for rare diseases
have been launched in European countries and the U.S.,
including patient access schemes, ring-fenced budgets
and patient assistance programs [31]. Novel patient assistance and foundation programs are supported by
patient organizations and drug manufacturers, such as
NORD’s Hodgkin’s Lymphoma Co-Payment Assistance
Program, and the Celgene Patient Support Program
(Revlimid), among others [38]. Since 1987, NORD has
administered over 380 patient assistance programs and
given out $56 million worth of drugs for free, as well as
offering co-payment assistance [39].
At present, in China, eight assistance programs for donated drugs have been developed by the China Charity Federation and drug manufacturers, and includes drugs such
as Glivec ®, Tasigna ®, Nexavar ®, Tracleer ®, Cerezyme ®,
Exjade ®, Iressa ® and Tarceva ®. In 2012, the Chinese government launched a new insurance scheme for all residents
that deals with serious illnesses. This pilot scheme benefits
patients with 20 serious and life-threatening diseases including childhood leukemia, breast cancer, cervical cancer,
esophageal cancer, colon and colorectal cancer, CML, and
HEM, among others. In 2013, imatinib mesylate and dasatinib obtained marketing authorization as generic drugs from
the CFDA, using a special review and approval procedure
[40]. On February 22, 2013, the CFDA also released a new
notice on establishing an accelerated approval process for
new drugs and a priority review of generic drugs for rare
diseases. As described above, the Chinese government is
paying more attention to the issue of orphan drugs.
Therefore, it is necessary that future policies can assure a
negotiated price for orphan drug with the pharmaceutical
companies, encourage marketing approvals of generics
with lower prices and establish a joint funding model that
includes government funding for specific medical insurance and social or private capital for patient assistance
programs, so as to lower the drug price and enhance the
affordability of orphan drugs.
Limitations

The availability of orphan drugs was measured at specific health facilities on the day of data collection. This
measure of availability may not accurately capture the
availability of medicines in the hospitals. The hospitals
surveyed may normally have a product in stock or have
a purchase contract with a drug company. However, they
may have run out of the drug on the day of the survey.
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We measured affordability based on the average and
high income level of residents, which may not reflect affordability for residents with lower incomes. Moreover,
our measure of affordability does not take into account
other diagnostic or treatment costs. The true cost of
health care for patients with rare diseases may have been
underestimated.
In this study, 31 orphan drugs were evaluated with
$0.002 to $881.3 unit procurement price. However, some
common and cheap drugs with indications for rare diseases
that had a unit procurement price below $0.002, were not
analyzed for their availability and affordability. Therefore,
the whole availability and affordability of orphan drugs may
be underestimated to some degree in China.

Conclusions
The article reveals that both the availability and affordability of orphan drugs in China are low. However, a good
medication should be both available and affordable. In the
absence of either factor, the drug is of little use to patients.
In this context, the Chinese government can take further
responsibility for improving the availability and affordability of orphan drugs through setting up incentive policies
and public platforms for the sharing of orphan drug information. Control of the price of orphan drugs and a joint
funding model from both government and private enterprise can efficiently reduce the economic burden of
affected patients in China.
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